Patented products for protein synthesis stimulation in eukaryotic cells (PROGENTERM © TECHNOLOGY)

   The development of newest technology of gene therapy PROGENTERM © was finalized in April 2016.
   PROGENTERM © technology is the more effective technology than classic plasmid DNA, vectors and viral DNA.

Patented line of products for stimulation of the synthesis in eukaryotic cells
such protein molecules as:

- insulin-like growth factor (IGF)
- erythropoetin (EPO)
- somatotropin ( SMT-h)
- vascular endothelial growth factor (VEGF)
- activated mTORC1 for stimulation of protein synthesis in general
- antibodies to myostatin
- antibodies to viral infections
- nervous system regeneration factor

Main advantages:

- High efficiency of DNA penetration in the cell.
- DNA doesn't integrate in the genome of the cell because of the special modification of the terminus.
- Duration of the work in the cells – no less than 7 days.

Fill in your application

Please, fill in your application
Do you want to get a specialist consultation?